Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of injection pens for the Danish drugmaker's next-generation experimental obesity drug CagriSema, a source familiar with the matter has told Reuters.

Novo Nordisk's (NVO) contract Ypsomed to supply the company with injection pens designed to deliver its next-gen obesity therapy CagriSema. Read mkore here.

Novo Nordisk's blockbuster weight-loss drug Wegovy is now available for use in China, the company confirmed to AFP on Tuesday, as the Asian nation battles high rates of obesity.A Novo Nordisk spokesperson confirmed to AFP on Tuesday that the drug was "now available in China" for the treatment of adults with obesity and those overweight with at least one weight-related comorbidity.

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing of its popular obesity and diabetes injections.

Novo Nordisk A/S is launching its top-selling Wegovy obesity drug in China at a fraction of the US price, a key step in unlocking a big, fast-growing market for its blockbuster franchise.

The first prescription for the drug in China will reportedly be issued at a public hospital in Shanghai this week and will cost about $193 for a one-month supply of the lowest dose.

Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest pharmaceuticals market where it estimates more than 180 million people live with obesity.

Novo Nordisk and Ypsomed’s 2023 deal is rumoured to include an autoinjector supply for potential Wegovy successor CagriSema.